Figure 2—Effect of treatments with dapagliflozin (DAPA) and glipizide (GLIP) with metformin
(MET) on hypoglycemia, reduction in body weight, and time to study discontinuation due to lack
of glycemic control at 52 weeks. A: Proportion of patients with at least one episode of hypoglycemia
at 52 weeks. *Difference vs. GLIP + MET, 237.2% (95% CI of difference 242.3 to 221.2;
P , 0.0001). B: Proportion of patients with $5% reduction in body weight at 52 weeks.
†Difference vs. GLIP + MET, 30.8% (95% CI of difference 26.0–35.7; P , 0.0001). Data are
adjusted proportions and 95% CI according to the methodology of Zhang et al. (15) using the full
analysis set and LOCF values. C: Time to study discontinuation due to lack of glycemic control.
Symbols represent censored observations. Week is not the scheduled visit week but the actual
number of days from the first dose of double-blind study medication divided by 7. Number of patients
at risk is the number of patients at risk at the beginning of the period.